[go: up one dir, main page]

MXPA03005505A - Compuesto modafinilo y mezclas de ciclodextrina. - Google Patents

Compuesto modafinilo y mezclas de ciclodextrina.

Info

Publication number
MXPA03005505A
MXPA03005505A MXPA03005505A MXPA03005505A MXPA03005505A MX PA03005505 A MXPA03005505 A MX PA03005505A MX PA03005505 A MXPA03005505 A MX PA03005505A MX PA03005505 A MXPA03005505 A MX PA03005505A MX PA03005505 A MXPA03005505 A MX PA03005505A
Authority
MX
Mexico
Prior art keywords
modafinil compound
cyclodextrin
cyclodextrin mixtures
mixtures
modafinil
Prior art date
Application number
MXPA03005505A
Other languages
English (en)
Inventor
J Jacobs Martin
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of MXPA03005505A publication Critical patent/MXPA03005505A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
MXPA03005505A 2000-12-19 2001-12-19 Compuesto modafinilo y mezclas de ciclodextrina. MXPA03005505A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25668100P 2000-12-19 2000-12-19
US10/023,441 US7141555B2 (en) 2000-12-19 2001-12-18 Modafinil compound and cyclodextrin mixtures
PCT/US2001/049189 WO2002056915A2 (en) 2000-12-19 2001-12-19 Complex of modafinil and cyclodextrin

Publications (1)

Publication Number Publication Date
MXPA03005505A true MXPA03005505A (es) 2003-10-06

Family

ID=26697157

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03005505A MXPA03005505A (es) 2000-12-19 2001-12-19 Compuesto modafinilo y mezclas de ciclodextrina.

Country Status (22)

Country Link
US (1) US7141555B2 (es)
EP (1) EP1368063B1 (es)
JP (1) JP4094428B2 (es)
KR (1) KR20040012696A (es)
CN (1) CN100384477C (es)
AT (1) ATE396745T1 (es)
AU (1) AU2002246711B2 (es)
BG (1) BG108009A (es)
BR (1) BR0116698A (es)
CA (1) CA2432126C (es)
CZ (1) CZ20031878A3 (es)
DE (1) DE60134274D1 (es)
EA (1) EA200300705A1 (es)
ES (1) ES2305128T3 (es)
HU (1) HUP0401592A2 (es)
IL (1) IL156470A0 (es)
MX (1) MXPA03005505A (es)
NO (1) NO20032788L (es)
NZ (1) NZ526780A (es)
PL (1) PL362474A1 (es)
SK (1) SK9012003A3 (es)
WO (1) WO2002056915A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003213719A1 (en) 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20040116532A1 (en) 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
JP2004250390A (ja) * 2003-02-21 2004-09-09 Taisho Pharmaceut Co Ltd 鉄化合物配合内服液剤
EA009714B1 (ru) 2003-03-28 2008-02-28 Арес Трейдинг С.А. Препараты кладрибина для улучшенной пероральной доставки и доставки через слизистые оболочки
DE602004028448D1 (de) * 2003-03-28 2010-09-16 Ares Trading Sa Orale zubereitungen enthaltend cladribin
NZ545133A (en) * 2003-09-04 2009-12-24 Cephalon Inc Modafinil compositions
BRPI0413777A (pt) * 2003-09-04 2006-11-07 Cephalon Inc composições de modafinil
US7566805B2 (en) 2003-09-04 2009-07-28 Cephalon, Inc. Modafinil compositions
US8153159B2 (en) 2003-09-18 2012-04-10 Cephalon, Inc. Modafinil modified release pharmaceutical compositions
US20090018202A1 (en) 2004-02-06 2009-01-15 Cephalon, Inc. Modafinil compositions
MXPA06012777A (es) * 2004-05-06 2007-02-14 Cydex Inc Formulaciones de sabor enmascarado que contienen sertralina y eter sulfoalquilico-ciclodextrina.
US20060024370A1 (en) * 2004-07-29 2006-02-02 Cephalon France Modafinil oral lyophilizate
CN100503647C (zh) * 2005-11-02 2009-06-24 南京师范大学 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
KR20090031618A (ko) * 2006-07-12 2009-03-26 엘란 코포레이션, 피엘씨 나노입자형 모다피닐 제제
JP2009091309A (ja) * 2007-10-10 2009-04-30 Japan Organo Co Ltd バコパモニエラエキスを含有する組成物およびその製造方法ならびに飲食品
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
US8975241B2 (en) 2009-10-08 2015-03-10 Song Ho Biomed Co., Ltd. Composition for treating and preventing obesity including high water-soluble 2-hydroxypropyl-betacyclodextrin as effective component
KR101026864B1 (ko) * 2009-10-08 2011-04-12 (주)송호바이오메드 고 수용성 ２―하이드록시프로필―베타사이클로덱스트린을 유효성분으로 함유하는 비만 질환 예방 및 치료용 조성물
EP3210597A1 (en) 2010-09-13 2017-08-30 Bev-RX, Inc. Aqueous drug delivery system comprising off- flavor masking agent
US9474715B2 (en) 2011-11-30 2016-10-25 Andreas Voigt Polymeric drug-delivery material, method for manufacturing thereof and method for delivery of a drug-delivery composition
US9364549B2 (en) 2011-11-30 2016-06-14 Andreas Voigt Hydrophobic drug-delivery material, method for manufacturing thereof and methods for delivery of a drug-delivery composition
US9616068B2 (en) 2014-10-27 2017-04-11 Pohela LLC Animal training using cognitive enhancement
KR101719987B1 (ko) 2015-08-03 2017-03-27 (주)상전정공 화물차량의 잠금장치
US9855228B1 (en) 2016-12-14 2018-01-02 Taho Pharmaceuticals Ltd. Oral solution comprising atomoxetine hydrochloride and methods thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5835968B2 (ja) * 1974-02-25 1983-08-05 帝人株式会社 サイクロデキストリン包接化合物の製造法
GB1584462A (en) 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
JPS5920230A (ja) 1982-07-19 1984-02-01 チバ−ガイギ−・アクチエンゲゼルシヤフト ピルプロフエン含有薬剤
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
FR2593809B1 (fr) * 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
JPS62281855A (ja) * 1986-05-29 1987-12-07 Daikin Ind Ltd ビタミン，ビタミン誘導体，またはホルモンを含有する包接化合物
GB8813682D0 (en) * 1988-06-09 1988-07-13 Reckitt & Colmann Prod Ltd Pharmaceutical compositions
JPH035438A (ja) * 1989-05-31 1991-01-11 Kaken Pharmaceut Co Ltd フルルビプロフェン包接化合物およびこの包接化合物を用いる消炎鎮痛剤
SE8902235D0 (sv) * 1989-06-20 1989-06-20 Haessle Ab Novel cyclodextrin inclusion complexes
FR2663225B1 (fr) 1990-06-14 1994-11-04 Lafon Labor Nouvelle utilisation du modafinil.
US5024997A (en) 1990-06-22 1991-06-18 American Home Products Corporation Palatable ibuprofen solutions
FR2684875B1 (fr) * 1991-12-13 1995-05-24 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique.
US5843347A (en) 1993-03-23 1998-12-01 Laboratoire L. Lafon Extrusion and freeze-drying method for preparing particles containing an active ingredient
FR2702968B1 (fr) 1993-03-23 1995-06-23 Lafon Labor Procédé de préparation de particules renfermant un ingrédient actif par extrusion et lyophilisation .
US5866162A (en) 1993-08-10 1999-02-02 Smithkline Beecham P.L.C. Pharmaceutical composition containing a drug/β-cyclodextrin complex in combination with an acid-base couple
US5618845A (en) 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
US6077871A (en) 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
US6200968B1 (en) 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6346548B1 (en) * 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
US6455588B1 (en) * 1999-08-20 2002-09-24 Cephalon, Inc. Compositions including modafinil for treatment of eating disorders and for appetite stimulation

Also Published As

Publication number Publication date
AU2002246711B2 (en) 2006-12-14
CN100384477C (zh) 2008-04-30
CA2432126C (en) 2011-03-08
JP4094428B2 (ja) 2008-06-04
NZ526780A (en) 2005-07-29
JP2004525104A (ja) 2004-08-19
NO20032788D0 (no) 2003-06-18
HK1059055A1 (en) 2004-06-18
HUP0401592A2 (hu) 2004-11-29
NO20032788L (no) 2003-07-07
WO2002056915A2 (en) 2002-07-25
US7141555B2 (en) 2006-11-28
IL156470A0 (en) 2004-01-04
KR20040012696A (ko) 2004-02-11
CZ20031878A3 (cs) 2004-10-13
BG108009A (en) 2004-09-30
SK9012003A3 (en) 2003-12-02
ES2305128T3 (es) 2008-11-01
BR0116698A (pt) 2003-10-21
EP1368063B1 (en) 2008-05-28
US20020160982A1 (en) 2002-10-31
CA2432126A1 (en) 2002-07-25
WO2002056915A3 (en) 2003-01-03
DE60134274D1 (en) 2008-07-10
CN1486196A (zh) 2004-03-31
PL362474A1 (en) 2004-11-02
EA200300705A1 (ru) 2003-12-25
ATE396745T1 (de) 2008-06-15
EP1368063A2 (en) 2003-12-10

Similar Documents

Publication Publication Date Title
MXPA03005505A (es) Compuesto modafinilo y mezclas de ciclodextrina.
CY1110061T1 (el) Συνθεσεις περιλαμβανοντας ενωσεις μοδαφινιλης
AU2001270070A1 (en) Nitrosated and nitrosylated taxanes, compositions and methods of use
AU7007001A (en) Nitrosated and nitrosylated taxanes, compositions and methods of use
ATE264863T1 (de) 28-epirapaloge
DE60112893D1 (de) Quetschventil
PL343466A1 (en) Substituted benzamides, their production and their use as cysteine protease inhibitors
SG146442A1 (en) Sulphonamide derivatives, their preparation and use as medicaments
DE60132618D1 (de) 4,6-diphenylpyridinderivate als entzündungshemmende mittel
AU5218001A (en) Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals
CY1106056T1 (el) Παραγωγα 2-αμινο-2-αλκυλ-5-επτενοϊκου και επτυνοϊκου οξεος χρησιμα σαν αναστολεις συνθασης νιτρικου οξειδιου
IL154240A0 (en) 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods
EE200300060A (et) Polaarsete rühmadega perfluoroalküülrühma sisaldavad kompleksid, nende valmistamismeetod ja kasutamine
BG66081B1 (bg) Състави, съдържащи модафинилни съединения
MXPA04005942A (es) Composiciones y metodos de sintaxina 3.
AU2002210491A1 (en) Agent having prolonged stomach retention time used to produce a longlasting saturation effect, and the use thereof
IT1318578B1 (it) Articolatore, particolarmente per le applicazioni in odontoiatria eodontotecnica.
NO20021429L (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
EP1556022A4 (en) Aqueous 2,6-diisopropylprophenol-containing pharmaceutical compositions
ES1046758Y (es) Cepillo interdental.
ZA200303830B (en) New mandelic acid derivatives and their use as thrombin inhibitors.
ES1045154Y (es) Sacacorchos neumatico perfeccionado.
IT1316878B1 (it) Composizione per uso topico a base di acido linoleico e/o lipoico.
DK1177185T3 (da) 4,5,6,7-tetrahydroindazolderivater som antitumormidler
SE0003877D0 (sv) New composition, method and use

Legal Events

Date Code Title Description
FG Grant or registration